An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients
Document Type
Journal Article
Publication Date
1-1-2015
Journal
Cancer Treatment Communications
Volume
4
DOI
10.1016/j.ctrc.2015.11.003
Keywords
Castrate-resistant; Everolimus; Pasireotide; Phase II; Prostate cancer
Abstract
© 2015 Elsevier Ltd. New areas of research continue to examine the role of non-androgen receptor pathways in prostate cancer treatment. The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway may be a target for prostate cancer therapy. Somatostatin receptor signaling inhibits intracellular PI3K/Akt signaling, making it an attractive target for combination therapy. We conducted a phase II open label clinical trial examining the use of somatostatin receptor agonist, pasireotide (SOM230) in combination with mTOR inhibitor, everolimus in metastatic castrate-resistant chemotherapy-naïve prostate cancer patients. Of the 6 patients enrolled in the study, only 1 patient had >50% PSA reduction from baseline. Three patients withdrew due to grade 3 adverse events. The study was closed early due to toxicity profiles and no further development was planned for this combination treatment in prostate cancer.
APA Citation
Lin, J., Deng, A., Hoffman-Censits, J., Gibney, G., Hyslop, T., Miller, B., Kilpatrick, D., Jabbour, S., & Kevin Kelly, W. (2015). An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients. Cancer Treatment Communications, 4 (). http://dx.doi.org/10.1016/j.ctrc.2015.11.003
